Mediaboss Marketing

GE Healthcare, an integral part of General Electric Company ( GE ), recently announced that it has received the European Union's approval for marketing its VIZAMYL (Flutemetamol (18F) Solution for Injection). VIZAMYL is a radiopharmaceutical medicinal product for Positron Emission Tomography (PET) imaging of beta amyloid plaque in brains of adult patients suffering from cognitive diseases. VIZAMYL will enable patients to get a neurological diagnosis of diseases such as Alzheimer's (AD).

General Electric's VIZAMYL is the only diagnostic PET imaging tracer approved in the Euproean Union for detection of beta amyloid and visual interpretation of colour images. Along with the commercial launch of VIZAMYL in early 2015, GE Healthcare has also developed a mandatory electronic reader training program (ETP) for readers of VIZAMYL images.

GE Healthcare provides transformational medical technologies and services by ensuring greater access to enhanced quality and affordable healthcare facilities across the globe. The approval is likely to further expand the scope of innovative diagnostic technologies for more accurate assessment of specific patients evaluated for Alzheimer's disease and support further research into the required disease modifying agents.

General Electric, the parent company of GE Healthcare, is one of the most diversified technologies and financial service corporations in the world. Its segments include Power & Water, Oil & Gas, Energy Management, Aviation, Healthcare, Transportation, Home & Business Solutions, and GE Capital.

General Electric currently has a Zacks Rank #3 (Hold). Other stocks that look promising in the industry include Federal Signal Corp. ( FSS ), Macquarie Infrastructure Company LLC. ( MIC ) and ITT Corporation ( ITT ), each having a Zacks Rank #2 (Buy).

ITT CORP (ITT): Free Stock Analysis Report

GENL ELECTRIC (GE): Free Stock Analysis Report

FED SIGNAL CP (FSS): Free Stock Analysis Report

MACQUARIE INFRA (MIC): Free Stock Analysis Report

To read this article on Zacks.com click here.

More:
GE Healthcare Gets European Union Approval for VIZAMYL - Analyst Blog